Novo Nordisk, Eli Lilly fall after Trump comments on weight loss drug pricing
Investing.com - H.C. Wainwright has reiterated its Buy rating and $40.00 price target on Briacell Therapeutics (NASDAQ:BCTX), representing significant upside from the current price of $11.29. According to InvestingPro data, analyst targets range from $40 to $150, with the company valued at approximately $20 million in market cap.
Briacell announced on October 13 that it will present the updated data from its study of Bria-IMT plus checkpoint inhibitors versus physician’s choice for metastatic breast cancer treatment on October 20 at 12 pm CET. The presentation comes just days before the company’s next earnings release, scheduled for October 27, as tracked by InvestingPro, which also notes the company holds more cash than debt on its balance sheet.
According to the abstract published over the weekend, 122 patients have been screened and 79 randomized, with data available from 68 patients who had a median of six prior lines of therapy. This represents an increase from the 62 evaluable patients reported at the American Association for Cancer Research (AACR) meeting in April.
The abstract noted that patients who were DTH+ (delayed-type hypersensitivity positive) experienced statistically significant improvements in progression-free survival across all treatment arms (p=0.0002). The median progression-free survival for the overall cohort was 3.2 months, down from the previously reported 3.67 months.
Briacell’s treatment demonstrated a consistent safety and tolerability profile with previous updates, with no interstitial lung disease or central nervous system complications observed in patients.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.